Irinotecan Hydrochloride Injection, Solution
Product Images NDC 60505-6272

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Irinotecan Hydrochloride (NDC 60505-6272). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

5ml-carton (5ml Carton)

5ml-carton (5ml Carton)
Packaging label for Irinotecan Hydrochloride Injection, USP, 100 mg/5 mL (20 mg/mL), an intravenous solution. The label includes dosage, storage instructions, and warnings, specifying single-dose use and cytotoxic caution. Manufactured by Qilu Pharmaceutical in China for Apotex Corp., Weston, Florida. The label features a barcode and product NDC 60505-6272-1 with branding in orange, white, and teal colors.*
FDA Label Image

5ml-container (5ml Container)

5ml-container (5ml Container)
Label for Irinotecan Hydrochloride Injection, USP 100 mg/5 mL (20 mg/mL) intravenous solution by Apotex Corp. The label includes usage instructions indicating dilution is required before use, and notes the drug is cytotoxic and for single-dose use with discard instructions. Manufacturer information is provided, including Qilu Pharmaceutical (Hainan) Co., Ltd., China, and Apotex Corp., Florida, USA.*
FDA Label Image

Figure 1 Survival First-line Irinotecan/5-fu/lv Vs 5-fu/lv Study 1 (Figure 1)

Figure 1 Survival First-line Irinotecan/5-fu/lv Vs 5-fu/lv Study 1 (Figure 1)
A survival curve chart comparing first-line Irinotecan/5-FU/LV versus 5-FU/LV alone over time in months. The y-axis shows probability from 0 to 1, and the x-axis shows months up to 42. Two declining curves represent survival probabilities for each treatment group, indicating a statistical comparison with p<0.05 by log-rank test.*
FDA Label Image

Figure 2 Survival First-line Irinotecan/5-fu/lv Vs 5-fu/lv Study 2 (Figure 2)

Figure 2 Survival First-line Irinotecan/5-fu/lv Vs 5-fu/lv Study 2 (Figure 2)
A survival curve chart comparing first-line treatment with Irinotecan/5-FU/LV versus 5-FU/LV alone over 30 months. The vertical axis shows probability from 0.0 to 1.0, and the horizontal axis shows time in months from 0 to 30. The Irinotecan/5-FU/LV curve consistently stays above the 5-FU/LV curve, indicating higher survival probability. A p-value of less than 0.05 is noted, indicating statistical significance.*
FDA Label Image

Figure 3. Survival Second-line Irinotecan Vs Best Supportive Care (bsc) Study 7 (Figure 3)

Figure 3. Survival Second-line Irinotecan Vs Best Supportive Care (bsc) Study 7 (Figure 3)
A survival curve graph comparing second-line Irinotecan to Best Supportive Care (BSC) in Study 7. The y-axis represents probability, and the x-axis represents months up to 21. The graph shows higher survival probability over time for Irinotecan compared to BSC, with related statistics including patient numbers (N), median follow-up of 13 months, median survival of 9.2 months for Irinotecan and 6.5 months for BSC, and a p-value of 0.0001 from a log-rank test.*
FDA Label Image

Figure 4. Survival Second-line Irinotecan Vs Infusion 5-fu Study 8 (Figure 4)

Figure 4. Survival Second-line Irinotecan Vs Infusion 5-fu Study 8 (Figure 4)
A Kaplan-Meier survival curve chart comparing second-line Irinotecan and Infusion 5-FU treatments over 21 months. The y-axis shows the probability of survival, and the x-axis indicates time in months. The chart includes median follow-up times and patient counts for both treatments. A p-value from a log-rank test is noted.*
FDA Label Image

Irinotecan Hydrochloride Structural Formula (Irinotecan Hydrochloride)

Irinotecan Hydrochloride Structural Formula (Irinotecan Hydrochloride)
Chemical structure diagram of Irinotecan Hydrochloride showing its molecular framework including ring systems, functional groups, and attached hydrochloride and water molecules (3 H2O).*
FDA Label Image
Image Description (Logo)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.